Michael Zhuo Wang

Michael Zhuo Wang

Auto-generated profile, based on publicly available information

Michael Zhuo Wang

Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2010 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
MWMichael Zhuo Wang
Michael Zhuo Wang
XZXiaohua Zhu
Xiaohua Zhu
ASAnuradha Srivastava
Anuradha Srivastava
QLQiang Liu
Qiang Liu
JSJ. Mark Sweat
J. Mark Sweat
KWKarl A. Werbovetz
Karl A. Werbovetz
Arylimidamides (AIAs) represent a new class of molecules that exhibit potent antileishmanial activity (50% inhibitory concentration [IC 50 ], <1 μM) against both Leishmania donovani axenic amastigotes and intracellular Leishmania , the causative agent for human visceral leishmaniasis (VL). A systematic lead discovery program was employed to characterize in vitro and in vivo antileishmanial activities, pharmacokinetics, mutagenicities, and toxicities of two novel AIAs, DB745 and DB766. They were exceptionally active (IC 50 ≤ 0.12 μM) against intracellular L. donovani , Leishmania amazonensis , and Leishmania major and did not exhibit mutagenicity in an Ames screen. DB745 and DB766, given orally, produced a dose-dependent inhibition of liver parasitemia in two efficacy models, L. donovani -infected mice and hamsters. Most notably, DB766 (100 mg/kg of body weight/day for 5 days) reduced liver parasitemia in mice and hamsters by 71% and 89%, respectively. Marked reduction of parasitemia in the spleen (79%) and bone marrow (92%) of hamsters was also observed. Furthermore, these compounds distributed to target tissues (liver and spleen) and had a moderate oral bioavailability (up to 25%), a large volume of distribution, and an elimination half-life ranging from 1 to 2 days in mice. In a repeat-dose toxicity study of mice, there was no indication of liver or kidney toxicity for DB766 from serum chemistries, although mild hepatic cell eosinophilia, hypertrophy, and fatty changes were noted. These results demonstrated that arylimidamides are a promising class of molecules that possess good antileishmanial activity and desirable pharmacokinetics and should be considered for further preclinical development as an oral treatment for VL.

1 August 2010
Verified
Journal Article
Closed access
MPMary F Paine
Mary F Paine
MWMichael Zhuo Wang
Michael Zhuo Wang
CGClaudia N Generaux
Claudia N Generaux
DBDavid Boykin
David Boykin
WWW. David Wilson
W. David Wilson
RTRichard R. Tidwell
Richard R. Tidwell

16 October 2008 in Proteomics
Verified
Journal Article
Closed access
PDF file
MWMichael Zhuo Wang
Michael Zhuo Wang
JWJudy Qiju Wu
Judy Qiju Wu
JDJennifer B. Dennison
Jennifer B. Dennison
ABArlene S. Bridges
Arlene S. Bridges
SHStephen D. Hall
Stephen D. Hall
JHJames Edwin Hall
James Edwin Hall